avelumab

Open Access
Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
AKINORI MINATO, YUI MIZUSHIMA, YOSHIHIRO SUGITA, TOMOHISA TAKABA, TAKUO MATSUKAWA, KAZUMASA JOJIMA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, EIJI KASHIWAGI and NAOHIRO FUJIMOTO

In Vivo July 2025, 39 (4) 2123-2132; DOI: https://doi.org/10.21873/invivo.14008
Open Access
Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing
NOBUKI FURUBAYASHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, YUSHI FUJIMOTO, MOTONOBU NAKAMURA and TAKAHITO NEGISHI

In Vivo March 2025, 39 (2) 976-987; DOI: https://doi.org/10.21873/invivo.13903
Open Access
Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
AKINORI MINATO, DAICHI OHNO, KAZUKI MUROOKA, YUTAKA OKUMURA, TOMOHISA TAKABA, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, KENICHI HARADA and NAOHIRO FUJIMOTO

In Vivo July 2024, 38 (4) 1927-1934; DOI: https://doi.org/10.21873/invivo.13648

Main menu